Wealth Enhancement Advisory Services
CHRS icon

Wealth Enhancement Advisory Services’s Coherus Oncology CHRS Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$95.9K Buy
62,255
+8,684
+16% +$14.2K ﹤0.01% 3806
2026
Q1 		$92.7K Buy
53,571
+19,863
+59% +$35.3K ﹤0.01% 3334
2025
Q4 		$45.8K Buy
33,708
+5,322
+19% +$7.75K ﹤0.01% 3537
2025
Q3 		$48.5K Sell
28,386
-5,889
-17% -$6.55K ﹤0.01% 3435
2025
Q2 		$27.8K Buy
34,275
+1,026
+3% +$886 ﹤0.01% 3273
2025
Q1 		$26.8K Buy
33,249
+2,402
+8% +$2.76K ﹤0.01% 2898
2024
Q4 		$42.6K Buy
30,847
+15,214
+97% +$17.1K ﹤0.01% 2878
2024
Q3 		$16.3K Buy
+15,633
New +$21.4K ﹤0.01% 2684

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Wealth Enhancement Advisory Services's CHRS Position: Q2 2026 in Review

Wealth Enhancement Advisory Services increased its Coherus Oncology (CHRS) stake by 16% in Q2 2026, buying an estimated $14.2K and bringing the position to 62,255 shares worth $95.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3806.

Wealth Enhancement Advisory Services first reported a position in CHRS in Q3 2024 and has held it in 8 quarters since. 146 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • Wealth Enhancement Advisory Services held 62,255 shares of Coherus Oncology worth $95.9K as of Q2 2026.
  • Wealth Enhancement Advisory Services bought 8,684 Coherus Oncology shares in Q2 2026, an estimated $14.2K.
  • Coherus Oncology made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #3806 holding.
  • Wealth Enhancement Advisory Services first reported a position in Coherus Oncology in Q3 2024 and has held it in 8 quarters since.
  • 146 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.